Monopar Therapeutics Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2016 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Monopar Therapeutics quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2016 to Q4 2023.
  • Monopar Therapeutics Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $13.3M, a 19.1% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $13.3M +$2.12M +19.1% Dec 31, 2023 10-K 2024-03-28
Q4 2022 $11.1M +$3.42M +44.3% Dec 31, 2022 10-K 2024-03-28
Q4 2021 $7.72M +$2.5M +47.9% Dec 31, 2021 10-K 2023-03-23
Q4 2020 $5.22M +$2.65M +103% Dec 31, 2020 10-K 2022-03-24
Q4 2019 $2.57M +$877K +51.9% Dec 31, 2019 10-K 2021-03-25
Q4 2018 $1.69M +$690K +68.9% Dec 31, 2018 10-K 2020-03-27
Q4 2017 $1M +$466K +87% Dec 31, 2017 10-K 2019-02-26
Q4 2016 $535K Dec 31, 2016 10-K 2018-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.